LBPH — Longboard Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.05bn
- $729.88m
- 36
- 30
- 92
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.58 | ||
| Price to Tang. Book | 2.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.82% | ||
| Return on Equity | -30.04% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 3.75 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Directors
- Paul Sekhri NEC (63)
- Kevin Lind PRE (44)
- Brandi Roberts CFO (47)
- Chad Orevillo VPR
- Steven Spector GCN (55)
- Philip Perera OTH (68)
- Vincent Aurentz DRC (53)
- Jane Tiller DRC
- Corinne Le Goff IND (55)
- Casey Lynch IND (47)
- Phillip Schneider IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 3rd, 2020
- Public Since
- March 12th, 2021
- No. of Shareholders
- 2
- No. of Employees
- 50
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 38,880,054
- Address
- 4275 Executive Square, Suite 950, LA JOLLA, 92037
- Web
- https://www.longboardpharma.com/
- Phone
- +1 6195929775
- Auditors
- KPMG LLP
Upcoming Events for LBPH
Q3 2024 Longboard Pharmaceuticals Inc Earnings Release
Similar to LBPH
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Longboard Pharmaceuticals share price?
As of Today at 21:52 UTC, shares in Longboard Pharmaceuticals are trading at $20.81. This share price information is delayed by 15 minutes.
How has the Longboard Pharmaceuticals share price performed this year?
Shares in Longboard Pharmaceuticals last closed at $20.81 and the price had moved by +146.27% over the past 365 days. In terms of relative price strength the Longboard Pharmaceuticals share price has outperformed the S&P500 Index by +95.96% over the past year.
What are the analyst and broker recommendations for Longboard Pharmaceuticals?
The overall consensus recommendation for Longboard Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Longboard Pharmaceuticals dividend yield?
Longboard Pharmaceuticals does not currently pay a dividend.
Does Longboard Pharmaceuticals pay a dividend?
Longboard Pharmaceuticals does not currently pay a dividend.
When does Longboard Pharmaceuticals next pay dividends?
Longboard Pharmaceuticals does not currently pay a dividend.
How do I buy Longboard Pharmaceuticals shares?
To buy shares in Longboard Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Longboard Pharmaceuticals?
As of the previous close price of $20.81, shares in Longboard Pharmaceuticals had a market capitalisation of $809.09m.
Where are Longboard Pharmaceuticals shares listed?
Here are the trading details for Longboard Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LBPH
What kind of share is Longboard Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Longboard Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Longboard Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Longboard Pharmaceuticals is $44.22. That is 112.49% above the last closing price of $20.81.
Analysts covering Longboard Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.82 for the next financial year.
What is the trend in the Longboard Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Longboard Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +203.05%.
As of the last closing price of $20.81, shares in Longboard Pharmaceuticals were trading +44.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Longboard Pharmaceuticals PE Ratio?
The Longboard Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $20.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Longboard Pharmaceuticals?
Longboard Pharmaceuticals' management team is headed by:
- Paul Sekhri - NEC
- Kevin Lind - PRE
- Brandi Roberts - CFO
- Chad Orevillo - VPR
- Steven Spector - GCN
- Philip Perera - OTH
- Vincent Aurentz - DRC
- Jane Tiller - DRC
- Corinne Le Goff - IND
- Casey Lynch - IND
- Phillip Schneider - IND